geographic atrophy
Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
January 22, 2026Research and Development Complement Therapeutics, FDA, Opthalmology, geographic atrophy
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), …
Eyestem secures $10m to advance cell therapy for advanced eye disease
August 13, 2025Medical Communications, Research and Development Eyestem, Opthalmology, cell therapy, dry age-related macular degeneration, geographic atrophy
Indian cell therapy company, Eyestem Research, has raised $10m in a funding round to support development of its investigational retinal …
Eyestem completes phase 1 trial of retinal cell therapy with promising vision gains
June 20, 2025Research and Development Eyestem Research, Opthalmology, cell therapy, clinical trial, dry age-related macular degeneration, geographic atrophy
Eyestem Research has announced the successful completion of its phase 1 trial evaluating Eyecyte-RPE, an investigational cell therapy for geographic …
Astellas announces FDA approval for Izervay for GA treatment
August 7, 2023Medical Communications AMD, Astellas Pharma, FDA, Izervay, Opthalmology, geographic atrophy
Astellas Pharma has announced that the US Food and Drug Administration (FDA) has approved Izervay (avacincaptag pegol intravitreal solution) for …
Janssen scoops up rights to Hemera’s gene therapy for retinal geographic atrophy
December 3, 2020Sales and Marketing Hemera Biosciences, Janssen, Retina, geographic atrophy
Janssen is set to acquire the rights to Hemera Biosciences’ intravitreal gene therapy injection HMR59, the company has announced, to …
